BOWIE, Md.--(BUSINESS WIRE)--Inovalon Powers 70% of Medicare Advantage Enrollees in 4+ Star Plans, Continuing to Outperform National Averages in 2026 CMS Star Ratings . ...

公司业务与竞争格局 - Phreesia Inc 是一家医疗保健技术公司，提供患者登记和互动平台，旨在简化患者体验并改善医疗结果 [1] - 公司在竞争格局中面临包括 Health Catalyst、Veracyte、Accolade、Castle Biosciences 和 Personalis 在内的多个同行，各公司财务指标各异 [1] 资本回报效率分析 - Phreesia 的投资资本回报率为 0.52%，显著低于其 7.01% 的加权平均资本成本，表明公司当前产生的回报未能超过其资本成本 [2] - Phreesia 的 ROIC 与 WACC 比率为 0.074，进一步凸显了资本利用效率低下 [2] - Health Catalyst 的 ROIC 为负 16.99%，WACC 为 6.57%，ROIC 与 WACC 比率为负 2.59，在创造超过资本成本的回报方面表现比 Phreesia 更差 [3] - Veracyte 的 ROIC 为 0.99%，WACC 为 13.50%，ROIC 与 WACC 比率为 0.073，尽管比率略低于 Phreesia，但仍表明其回报不足以覆盖资本成本 [4] - Accolade、Castle Biosciences 和 Personalis 的 ROIC 均为负值，分别为负 31.79%、负 4.28% 和负 30.51%，其 ROIC 与 WACC 比率分别为负 2.91、负 0.48 和负 2.60，表明在创造超过资本成本的回报方面面临重大挑战 [5] 行业整体状况 - Phreesia 及其同行普遍面临资本回报挑战，ROIC 低于或显著低于 WACC 的情况在行业中常见 [6] - 在同行公司中，Veracyte 显示出最高的增长潜力，尽管其 ROIC 与 WACC 比率仅为 0.073 [6]

Shareholder Update Reports Positive Customer Reviews, New Segment Growth and Technology Rollouts across Post-Acute HealthcareDETROIT, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, announces a 69% QoQ increase in revenue even as it reduced its spending. Amesite also reported expanding its customer base and offerings to post-acute health businesses across the U.S. The Company described these results and its pathway to offer the first AI- ...

Waystar Holding (NasdaqGS:WAY) Q3 2025 Earnings Call October 29, 2025 04:30 PM ET Company ParticipantsElizabeth Anderson - Senior Managing DirectorAdam Hotchkiss - VP of Equity ResearchSue Dooley - VP of Investor RelationsCharles Rhyee - Managing DirectorSteve Oreskovich - CFOBrian Peterson - Financial AdvisorMatt Hawkins - CEOJailendra Singh - Managing DirectorConference Call ParticipantsVikram Kesavabhotla - Senior Research AnalystSaket Kalia - Equity Research AnalystRyan Daniels - AnalystAllen Lutz - Equ ...

Vsee Health Inc (NASDAQ: VSEE) more than doubled after receiving FedRAMP High Authority to Operate (ATO) from the US Department of Health and Human Services (HHS) on Wednesday. While that opens doors ... ...

MILWAUKEE--(BUSINESS WIRE)-- #NextGenHealthcare--NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, has been selected by Aambé Health to accelerate its work building and scaling clinics, pharmacies, and employee wellness programs in Native American communities nationwide. A division of Aambé Corporation, Aambé Health collaborates with Tribal Nations to improve existing healthcare infrastructure and establish new facilities and programs. With NextGen Healthcare ...

ALPHARETTA, Ga., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Heald, the human-led, tech-enabled platform redefining Diabetes care, proudly announces that Dr. Sunita Mishra, former Chief  Medical Officer of Amazon Health services and CMO for  Amazon Care, has joined as an Advisory Board Member. In this role, Dr. Mishra will advise on Heald’s expansion into the employer, provider, and health system markets, bringing her deep expertise in scaling hybrid care models that connect digital technology with real human care. ...

公司评级与目标价 - Canaccord Genuity分析师Kyle Mikson重申对Tempus AI的买入评级 目标价为110美元 [1] - 公司股票代码为纳斯达克TEM [1][3] 业务模式与增长驱动力 - 公司是一家医疗保健技术公司 提供人工智能赋能的精准医疗解决方案 [3] - 核心业务包括肿瘤学基因组分析测试、数据服务以及人工智能应用 [3] - 临床实践中大规模部署人工智能的潜力有望推动公司长期收入强劲增长 [1][3] 发展战略与财务预测 - 积极的收购策略是加速增长的关键 例如收购Ambry可扩展测试能力并增强人工智能功能 [2][3] - 现金流折现模型的关键假设包括10年收入复合年增长率为22.8% 峰值营业利润率达45.6% 折现率为15.0% [3]

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report third quarter 2025 operating results after stock market trading hours on Tuesday, Nov. 4. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full e ...

收购事件概述 - ThinkBioAi公司收购了英国InfoHealth Solutions公司[1] - 被收购方InfoHealth Solutions为英国国民医疗服务体系提供医院资产管理软件 支持19个NHS信托机构并拥有超过30个活跃安装项目[1] - 收购后InfoHealth Solutions将保留其品牌身份 作为ThinkBioAi旗下的公司运营[1] 战略意义与市场拓展 - 此次收购使ThinkBioAi能够将其解决方案套件引入英国医疗保健领域 包括Advice&Guide、Patient Panorama和Healia等产品[1] - 该协议扩大了ThinkBioAi的国际影响力 彰显了其致力于在英国、美国及其他地区推进下一代医疗基础设施解决方案的决心[4] - 公司目标是结合InfoHealth的基础与自身AI能力 在未来几年成为英国医疗市场的重要参与者[3] 产品与技术整合 - 相关平台旨在增强运营弹性并支持NHS信托机构和私营医疗提供商的资源规划[2] - Patient Panorama作为一个统一的临床智能仪表板 整合了预测性洞察、患者数据和护理工作流程[2] - Healia是AI驱动的虚拟护理平台 可提高临床效率和患者参与度[2] - Advice&Guide提供基于AI的临床指导 以改善患者护理服务、优化全科医生转诊并减轻医院压力[3] 未来合作与发展 - 两家公司计划推出先进工具 旨在提高医院资产效率、预测设备故障并简化维护计划[4] - 整合后的专业知识将帮助医院以更高的可靠性和智能性满足日益增长的患者需求[4] - InfoHealth的客户将继续受益于由ThinkBioAi的AI方法改进的无缝服务[3]